Biosphere businesses receive funding boost to support the global fight against COVID-19

TWO businesses based in The Biosphere on Newcastle Helix have been awarded funding to accelerate their innovations to support the global fight against the COVID-19. Innovate UK, the UK’s innovation agency has awarded ExplantLab and Atelerix almost £50,000 each to fast track their ideas and research.

CEO Update|Monday 01 June

The NHS Test and Trace Programme is launched, Gilead’s remdesivir becomes available under the Early Access to Medicines Scheme and BIA members continue to ramp up UK vaccine manufacturing capacity. Plus, the BIA innovates this week with the popular Women in Biotech series moving to a virtual setting!

Guest Blog|Reducing the use of animals in drug development whilst ensuring human safety

The use of animals in research continues to rank highly in the public consciousness, with a 2018 Ipsos MORI poll showing that three-fifths of people are interested in the methods used by scientists to replace, reduce and refine the use of animals in research (the 3Rs). The UK’s National Centre for the Replacement, Refinement and Reduction of Animals in Research (the NC3Rs) is committed to furthering this goal. Its programme includes a long-standing collaboration with the pharmaceutical industry that has led to changes in company practice and regulatory guidelines.

CEO Update|Tuesday 26 May

AstraZeneca receives $1.2bn to scale-up and deliver Oxford’s COVID-19 vaccine, antibody testing gains momentum as a deal is struck between Roche and the NHS and details start to emerge on the future of the UK’s relationship with the EU.

Guest Blog|A reflection on the Lighthouse Lab journey so far

Last month, UK government approached Medicines Discovery Catapult, based at Alderley Park, to coordinate the establishment of the national megalabs for the testing of COVID-19.

BIA welcomes new NIHR framework for restarting research activities in the UK

Commenting on the NIHR 'Framework for restart' released today, Steve Bates OBE, Chief Executive of the BIA said: 

Guest Blog|How do pandemics impact the life sciences industry?

Pharmaceutical, healthcare and biotech companies are at the forefront of the COVID-19 response, from therapeutic drug trials and vaccine development to the production of personal protective equipment (PPE) and ventilators.

BIA responds to government approach to Northern Ireland Protocol

Commenting on the Government’s approach to the Northern Ireland Protocol released yesterday, Steve Bates OBE, Chief Executive of the BioIndustry Association said:

Oxford Immunotec releases the T-SPOT® Discovery™ SARS-CoV-2 kit for research into measuring the T cell immune response to SARS-CoV-2, which may offer new insights into immunity to COVID-19

Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announces the release of the T-SPOT Discovery SARS-CoV-2 test kit. This kit is for research use only and launched under the T-SPOT Discovery brand. This research kit could make a significant contribution towards development of a new tool to manage the COVID-19 pandemic, which in turn could help to bring nations out of their current lockdowns in a faster, safer and more controlled manner.

BIA welcomes financial support for biotechs during COVID-19 disruption

A new support fund for innovative firms struggling to access equity finance during the COVID-19 disruption has opened for applications today (20 May). The Future Fund, run by the British Business Bank, will provide convertible loans of between £125,000 and £5m to businesses if they can also secure matched funding from third-party investors.